The left appendage occlusion device is used in procedures such as percutaneous transluminal left atrial appendage occlusion and thoracoscopic left atrial appendage closure. Left appendage occlusion device controls the electrical impulses during atrial fibrillation. During atrial fibrillation, blood clots are pumped out of the heart. This blood can form clots in the atria and LAA. This medical condition can cause a stroke. Left appendage occlusion device is an interventional device used to prevent stroke in atrial fibrillation. Left appendage occlusion device helps in reducing the risk of secondary stroke and emboli because of atrial fibrillation.
The global left appendage occlusion device market is expected to grow rapidly during the forecast period. Clinical evidence of the efficiency of left appendage occlusion devices compared to the standard therapeutic treatment such as warfarin and dabigatran increased awareness levels, and new product launches in new countries are key factors boosting the market growth. However, the complicated implantation procedures and need of experienced surgeons are restraining factors for the market. The stringent regulation procedures for the approval of devices are hindering the new product launches. The vendors focus on clinical trials for new product launches in the high potential market such as the US and the Asia Pacific.
The global left appendage occlusion device market is segmented on the basis of brand, distribution channel, and region. Based on the brands, the market is divided into Sierra, AtriClip, WaveCrest, Amplatzer Amulet, WATCHMAN, Ultrasept, LAmbre, and LARIAT. On the basis of distribution type, the market is segmented into Hospitals, Ambulatory Surgical Centers, and Heart Clinics. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, North America held the largest share of the market, followed by Europe. On the other hand, Asia-Pacific is expected to dominate the market during the analysis of the forecast period.
The key players of this market include Atricure, Biosense Webster, Boston Scientific, Abbott Laboratories, Aegis Medical, Cardia, Lifetech Scientific, and Sentreheart.